Home Online Features Vytala achieves a milestone with successful launch of Seracal and initiates IRB-approved study to expand its use across broader patient population
Vytala achieves a milestone with successful launch of Seracal and initiates IRB-approved study to expand its use across broader patient population
Press Releases
March 18, 2025

Vytala achieves a milestone with successful launch of Seracal and initiates IRB-approved study to expand its use across broader patient population

By Vytala

Seracal™, based on Lym-X-Sorb®, contains a proprietary lipid technology invented by David Yesair Ph.D. and exclusively licensed by Vytala

bradford

The Bradford Era

email
More by this Author
Local & Social